Delving into the Latest Updates on BI-764198 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BI 764198, BI-764198, BI764198

Target

TRPC6

Mechanism

TRPC6 antagonists(transient receptor potential cation channel subfamily C member 6 antagonists)

Therapeutic Areas

Urogenital DiseasesOther Diseases

Active Indication

Chronic Kidney DiseasesGlomerulosclerosis, Focal SegmentalGlomerular disease

Inactive Indication

COVID-19Respiratory DiseasesRespiratory Distress Syndrome, Adult

Originator Organization

Boehringer Ingelheim International GmbH

Active Organization

Boehringer Ingelheim GmbHAlmac Pharma Services Ltd.Boehringer Ingelheim International GmbH

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The main objective of this trial is to investigate the basic pharmacokinetics of BI 764198 and its metabolites, total radioactivity including mass balance, excretion pathways and metabolism following oral administration to healthy male volunteers of a single oral dose of BI 764198 (C-14) in i) a classical hADME approach and ii) a hADME microtracer approach.

Start Date03 May 2023

Sponsor / Collaborator

Boehringer Ingelheim GmbH

CTR20230035 / Active, not recruitingPhase 2

一项在局灶性节段性肾小球硬化症患者中评估BI 764198每日一次口服给药12周的有效性、安全性、耐受性、药代动力学和药效学特征的多中心、随机、双盲、平行分组、安慰剂对照研究

[Translation] A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of BI 764198 orally administered once daily for 12 weeks in patients with focal segmental glomerulosclerosis

本研究的主要目的是探索3种剂量的BI 764198在降低蛋白尿方面的有效性

[Translation]

The primary objective of this study was to explore the effectiveness of 3 doses of BI 764198 in reducing proteinuria.

Start Date11 Apr 2023

Sponsor / Collaborator

Boehringer Ingelheim (China) Investment Co., Ltd.

[+2]

100 Clinical Results associated with BI-764198

Login to view more data

100 Translational Medicine associated with BI-764198

Login to view more data

100 Patents (Medical) associated with BI-764198

Login to view more data

1

Literatures (Medical) associated with BI-764198

01 Dec 2023·Kidney international reports

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Article

Author: Desmond, Hailey E ; Kretzler, Matthias ; Choi, Wansuk ; Soleymanlou, Nima ; Manuel, Raymond C ; Trachtman, Howard

100 Deals associated with BI-764198

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	US	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	CN	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	AU	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	BE	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	FR	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	DE	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	IT	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	NZ	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	ES	Boehringer Ingelheim GmbH	03 May 2022
Chronic Kidney Diseases	Phase 2	GB	Boehringer Ingelheim GmbH	03 May 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04604184 (CTgov)	Phase 2	COVID-19 \| Respiratory Distress Syndrome, Adult	133	BI 764198 (BI 764198 Treatment Group)	knstsxesed(keynnucufn) = kwwcbgogeg yusrjdgomo (kisgftbceu, vfgrkqtvbn - gyaimyjrab) View more	-	11 Apr 2022
				Placebo (Placebo)	knstsxesed(keynnucufn) = njijezysjg yusrjdgomo (kisgftbceu, qlrksseire - dedbislgdl) View more